Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fibroblast Growth Factor (FGF) signaling is known to be critical in mediating key developmental events during craniofacial development. Recent evidence suggests that members of the Fibronectin (F) Leucine (L) Rich (R) Transmembrane (T), FLRT, family modulate FGF signaling.
FLRT2
has a highly specific pattern of expression during craniofacial development, in close relationship with FGFR2. We therefore characterized
FLRT2
/FGFR2 interactions in the context of craniofacial development and showed, by co-immunoprecipitation and
GST
pulldown assays with embryonic craniofacial tissue lysates, that
FLRT2
interacted with FGFR2. Yeast two-hybrid assays further showed that the intracellular regions of both proteins interacted in addition to the interactions in the extracellular portions. The extracellular Leucine Rich Repeats domain of
FLRT2
contributed to the interactions with the extracellular regions of FGFR2. Interactions in the intracellular regions of the 2 proteins were mediated by the C-tail domain in
FLRT2
. Furthermore, cells stably transfected with
FLRT2
shRNAs or
FLRT2
cDNA exhibited a concomitant decrease and increase, respectively, in FGFR2 protein, mRNA, and ERK phosphorylation levels, suggesting a positive feedback regulatory loop of
FLRT2
on FGF signaling in craniofacial tissues. We propose that
FLRT2
-FGFR2 interactions represent a potential mechanism for regulation of FGF signaling by
FLRT2
during craniofacial development.
...
PMID:Mouse FLRT2 interacts with the extracellular and intracellular regions of FGFR2. 2176 38